<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04349072</url>
  </required_header>
  <id_info>
    <org_study_id>MYK-461-017</org_study_id>
    <nct_id>NCT04349072</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy</brief_title>
  <acronym>VALOR-HCM</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MyoKardia, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MyoKardia, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, multi-center study in the United&#xD;
      States (U.S.) that will evaluate the effect of mavacamten treatment on reducing the number of&#xD;
      septal reduction therapy (SRT) procedures performed in subjects with symptomatic obstructive&#xD;
      hypertrophic cardiomyopathy (oHCM [also known as HOCM]) who are eligible for SRT based on&#xD;
      ACCF/AHA 2011 and/or ESC 2014 guidelines.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 26, 2020</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a parallel group treatment study with 2 treatment groups; subjects and investigators are blinded to treatment and dose for the first 16 weeks of treatment. Mavacamten dose is blinded throughout the study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Septal Reduction Therapy (SRT) Status</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Number of subjects who decide to proceed with SRT prior to or at Week 16 and the number of subjects who remain guideline eligible for SRT at Week 16.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SRT Status</measure>
    <time_frame>32 Weeks</time_frame>
    <description>Number of subjects who decide to proceed with SRT prior to or at Week 32 and the number of subjects who remain guideline eligible for SRT at Week 32.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mavacamten effect on NYHA</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Change from baseline to Week 16 in the mavacamten group compared with the placebo group in New York Heart Association (NYHA) class</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mavacamten effect on KCCQ</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Change from baseline to Week 16 in the mavacamten group compared with the placebo group in Kansas City Cardiomyopathy Questionnaire (KCCQ-23)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mavacamten effect on NT-proBNP</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Change from baseline to Week 16 in the mavacamten group compared with the placebo group in NT-proBNP and cardiac troponin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mavacamten effect on LVOT gradient</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Change from baseline to Week 16 in the mavacamten group compared with the placebo group in left ventricular outflow tract (LVOT) gradient</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>HOCM, Hypertrophic Obstructive Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Drug: Mavacamten</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mavacamten Capsules&#xD;
Other names:&#xD;
MYK-461</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo Capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mavacamten</intervention_name>
    <description>Mavacamten Capsules Other names: MYK-461</description>
    <arm_group_label>Drug: Mavacamten</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Drug: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  At least 18 years old at screening and body weight &gt; 45 kg at screening&#xD;
&#xD;
          -  Diagnosed with oHCM consistent with current ACCF/AHA 2011 and/or ESC 2014 guidelines&#xD;
             and meet their recommendations for invasive therapies&#xD;
&#xD;
          -  Referred or under active consideration within the past 12 months for SRT procedure and&#xD;
             willing to have SRT procedure&#xD;
&#xD;
          -  Has documented left ventricular ejection fraction (LVEF) ≥ 60% at Screening&#xD;
&#xD;
          -  Has documented oxygen saturation at rest ≥ 90% at Screening&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Persistent or permanent atrial fibrillation and subject not on anticoagulation for ≥ 4&#xD;
             weeks prior to screening and/or not adequately rate controlled ≤ 6 months prior to&#xD;
             screening&#xD;
&#xD;
          -  Previously treated with invasive septal reduction (surgical myectomy or percutaneous&#xD;
             alcohol septal ablation [ASA])&#xD;
&#xD;
          -  For individuals on beta blockers, calcium channel blockers, or disopyramide, any dose&#xD;
             adjustment of these medications &lt; 14 days prior to screening or an anticipated change&#xD;
             in regimen during the first 16 weeks of the study&#xD;
&#xD;
          -  Any medical condition that precludes upright exercise stress testing&#xD;
&#xD;
          -  Paroxysmal, intermittent atrial fibrillation with atrial fibrillation present at&#xD;
             screening&#xD;
&#xD;
          -  Prior treatment with cardiotoxic agents, such as doxorubicin or similar&#xD;
&#xD;
          -  Has a history or evidence of any other clinically significant disorder, condition, or&#xD;
             disease that would pose a risk to subject safety or interfere with the study&#xD;
             evaluation, procedures, or completion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine - Section of Cardiology</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Florida</name>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <zip>33331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Cardiovascular Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Cardiovascular Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spectrum Health Hospital</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49525</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westchester Medical Center.</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westchester Medical Center</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University School of Medicine</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania - Heart and Vascular Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Thomas West Hospital</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intermountain Medical Center</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 7, 2020</study_first_submitted>
  <study_first_submitted_qc>April 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2020</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Hypertrophic</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

